Buy or sell Freenome stock pre IPO via an EquityZen fund
EquityZen is a marketplace for shares of proven pre IPO tech companies
Freenome Stock
Multiomics Platform for Early Disease Screening
About Freenome Stock
Headquartered in South San Francisco, Freenome is a health technology company developing accurate, accessible and non-invasive disease screening products for proactively treating cancer and other diseases at their most manageable stages. Freenome aims to reinvent disease management through systematized early detection and intervention. Since launching in 2014, the company has raised more than $70 million from leading technology and healthcare investors.
Investors
Agent Capital
Allen & Company
Stripe, Vroom, Ginkgo Bioworks, Joby Aviation, Blend, Convoy, Freenome, Turo, OfferUp, Virta Health
AME Cloud Ventures
Wish, Zymergen, Recursion Pharmaceuticals, Freenome, Zume Inc., Planet, Illumio, Boxed, Mythic, Tile
Andreessen Horowitz
Lyft, Robinhood, Airbnb, Instacart, Magic Leap, Stripe, Databricks, Zenefits, Rappi, Pinterest
Asset Management Ventures (AMV)
Bain Capital Life Sciences
BrightEdge Fund
Catalio Capital Management
Charles River Associates
Cormorant Asset Management
CRV
DoorDash, Bird, Fair, Cybereason, Twitter, Airtable, ClassPass, Recursion Pharmaceuticals, Freenome, Niantic
EcoR1 Capital
Farallon Capital Management
Fidelity Management and Research Company
goPuff, Caris Life Sciences, Deliveroo, Freenome, Lime, Bowery Farming, ASAPP, Allbirds, ORIC Pharmaceuticals
Founders Fund
Lyft, SpaceX, Spotify, Airbnb, Stripe, Palantir Technologies, Wish, Compass, Zenefits, Flexport
GV
Uber, Robinhood, Jet, Impossible Foods, Slack, DocuSign, Cloudera, 23andMe, Collective Health, Recorded Future
Innovation Endeavors
Zymergen, Plenty, Getaround, Freenome, Yotpo, Mark43, Formlabs, Kong, Amprius, HomeLight
Janus Henderson Investors
Kaiser Permanente Ventures
Freenome, Proteus Digital Health, Vidyo, Nuvolo, Ginger, Vesta Healthcare
Longevity Vision Fund
Loxbridge Research
Novartis
Perceptive Advisors
Zymergen, Freenome, Omada Health, PROCEPT BioRobotics, AEGEA Medical, Saama
Polaris Partners
Freenome, Automattic, Club Factory, OM1, Egnyte, Quartet, Impinj, VeraCode, Xant, Drizly
RA Capital Management
Roche Venture Fund
Rock Springs Capital
S28 Capital
Sands Capital Management
Soleus Capital
T. Rowe Price
Flipkart, WeWork, Cruise, Airbnb, Rivian, Magic Leap, Caris Life Sciences, Vroom, Ginkgo Bioworks, Deliveroo
Verily
Funding History
| October 2015 | $800K |
|---|---|
| June 2016 | $5.6M |
| August 2017 | $72.0M |
| June 2019 | $165M |
| July 2020 | $270M |
Management
Chief Executive Officer
Mike Nolan
Chief Financial Officer
William Quirk
Press
chinamoneynetwork - Aug, 28 2020
cnbc - Feb, 1 2020
nanalyze - Oct, 8 2019
bioportfolio - Jul, 24 2019
businesswire - Jul, 12 2018
businesswire - Apr, 24 2018
businesswire - Mar, 29 2018
xconomy - Mar, 22 2018
wired - Jan, 17 2018
fiercebiotech - Dec, 11 2017
TechCrunch - Jul, 8 2017
nanalyze - Apr, 18 2017
Other Companies
EquityZen does not have an affiliation with, formal relationship with, or endorsement from Freenome or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
